Kingsman Scientific Management Announces Pitch Day for Central Alberta Businesses.

Blackfalds AB: Today, Kingsman Scientific Management, an Alberta-based business development firm that specializes in partnering with and investing in organizations who are seeking advanced growth in their respective industry, announced they will be having a Pitch Day, hosted by the Red Deer and District Chamber of Commerce on October 1, 2021.

Kingsman Scientific Management has developed a financing initiative to evaluate central Alberta companies seeking investment opportunities.  We are looking for businesses in the growth, established or mature stages that have been operating for a minimum of 3 years seeking financial and/or strategic support.

Kingsman Scientific Management will evaluate submissions and select companies for investment and strategic support in executing their plan and utilize internal expertise and established networks to influence the successful execution of planed initiatives.

The investment range is $25,000 to $75,000 per company with a total of $350,000 available for investment.  Use of funds requested can be used for but is not limited to:

1. Product &/or Service Development

2. Asset Purchases 

3. Working Capital

4. Growth Projects

5. Market Expansion

6. Increase Workforce

7. Research & Development

In addition, Kingsman Scientific Management will provide strategic and operational assistance in the execution of the business plans and partners we invest in.  Selected partners will benefit from our international network of experts spanning across a variety of industries in both public and private sectors and our internal team of experienced entrepreneurs and operators. 

For more information visit: https://www.kingsmansm.com/pitchday

Aspire Health Science Announces U.S. FDA Approval

ORLANDO, Florida, June 1, 2020 – Aspire Health Science, LLC (the “Company” or “Aspire”), an FDA registered cGMP manufacturing facility specialized in the research, development, and manufacturing of cell-based therapies, is thrilled to announce that it has received IND approval from the U.S. FDA to test the Company’s proprietary cellular therapy, ACT-20, against moderate to severe COVID-19 Pneumonia in a human trial.

According to the WHO Coronavirus Disease Situation 133 report (June 1, 2020), there have been over 6 million cases of COVID-19 globally, with an approximate death total of 372,000. Even more concerning, two separate studies displayed results that the average time from the first symptom to hospitalization was seven days*, while the average time from the first symptom to death was only fourteen days**.

The onset pandemic of COVID-19 presented the world with a complex challenge which lacked immediately viable solutions. In the wake of this unprecedented outbreak, it provoked Aspire to leverage their existing technological infrastructure and medical expertise in developing a cellular therapy to control COVID-19 Pneumonia. The Company’s decision to pursue treatment was validated by internal scientific evaluation of recent clinical study publications conducted by research and development teams in China, showing that MSCs (Mesenchymal Stem Cells) improves the outcome of patients with COVID-19 pneumonia by possibly controlling the cytokine storm.

Aspire’s proprietary product ACT-20 is an allogeneic cryopreserved cell preparation of Mesenchymal Stem Cells (MSCs) that are ex-vivo culture expanded from human umbilical cord tissue, and the conditioned media (MSC-CM) produced from the culture of the umbilical cord derived MSCs.

With the approval by U.S. FDA to move forward with onboarding clinical sites and treatment of human subjects, it marks a tremendous milestone for Aspire that showcases the Company’s ability to execute complex challenges under difficult conditions with an extremely aggressive timeline.

In this undertaking, Aspire aims to be the intersection between cell therapy application and crisis response, providing the medical community with solutions to prevalent gaps in treatment options. With a wealth of knowledge in developing and manufacturing cell-based therapies for specialized treatments used in human trials, Aspire is exceptionally motivated to begin Phase I of ACT-20 treatments and provide the necessary support to those requiring extensive aid.

Aspire is focused on being an industry leading CDMO and is currently searching for a Biotech partner in the cell therapy space to offer additional support for effective advancement of ACT-20 through clinical trials. Aspire will continue to expand its own CDMO capabilities and extend its services to the cellular therapy and regenerative medicine community.

ABOUT ASPIRE HEALTH SCIENCE, LLC

Aspire Health Science, LLC is an FDA registered manufacturing facility specialized in development and manufacturing of cell-based therapies. Aspire provides a one-stop shop for cell-based therapy development, manufacturing, logistics, analytical testing and regulatory support, bolstered by portfolio breadth, regulatory compliance, ability to execute & implement, and industry leading expertise.

Aspire Health Science Announces Strategic Partnership with NeoProgen for Development and Manufacturing of NeoProgen’s Cell-Based Therapy

ORLANDO, Florida, May 6th, 2020– Aspire Health Science, LLC (the “Company” or “Aspire”), an FDA registered GMP manufacturing facility specialized in the research, development and manufacturing of cell-based therapies, is pleased to announce a collaboration with NeoProgen, Inc.

NeoProgen, a Baltimore-based company led by Medtech entrepreneur Bill Niland, is a pre-clinical stage therapeutics company specializing in the development of novel cell-based cardiac therapies for heart regeneration.

Similar to Mr. Niland’s earlier venture with Harpoon Medical, NeoProgen has origins in research at the University of Maryland, Baltimore. That is where Dr. Sunjay Kaushal, a leading pediatric cardiac surgeon, discovered that a specific kind of neonatal cardiac progenitor/ stem cells (nCPCs), obtained from discarded cardiac tissue biopsies, are extremely effective in regenerating muscle tissue in the heart.

Under the terms of the agreement, Aspire is responsible for the cGMP manufacturing of a clinical grade Master Cell Bank from immortalized clonal isolate derived from human neonatal cardiac stem/progenitor cells for NeoProgen. Using this Master Cell Bank , the Company will also manufacture specific cell and cell-free (secretome) based therapies f for future clinical trials.

“We are excited to work with the Aspire team. It is clear that through working together with this specialized CDMO, we are on the path to developing a well characterized, scalable and sustainable process for our cell-based therapies.” says Bill Niland. Aspire has developed and manufactured cell-based therapies for both FDA and Health Canada clinical trials across multiple cell types. The research and development team has extensive experience in process development and cGMP manufacturing.

“We collaborate with clients and offer assistance in each step required to transition the therapy from the benchside to a scalable clinical grade therapy. Our goal is to help create a manufacturing process specific to client needs that will prioritize quality, cost of goods and sustainability, resulting in a commercially viable product.” Says Nermin Gerges, PhD, General Manager of Aspire Health Science, LLC.

ABOUT ASPIRE HEALTH SCIENCE, LLC Aspire Health Science, LLC is an FDA registered manufacturing facility specialized in development and manufacturing of cell-based therapies. Kingsman Scientific Management Inc. provides both strategic and high-level project management to support and accelerate development of novel technologies.

Cellular Therapy Against COVID-19 Pneumonia

ORLANDO, Florida, March 31st, 2020 – Aspire Health Science, LLC (the “Company” or “Aspire”), an FDA registered manufacturing facility specialized in the development and manufacturing of cell-based therapies, is pleased to announce that it has filed its pre-IND (Investigational New Drug) meeting request with the U.S. FDA and Pre-CTA (Clinical Trial Application) with Health Canada. A complete briefing package accompanied the meeting requests. This initiates formal communications between Aspire and both the U.S. FDA and Health Canada regarding development of the Company’s cellular therapy, ACT-20 for the treatment of severe COVID-19 Pneumonia.

The decision to file the ACT-20 clinical study with the U.S. FDA and Health Canada, was made in light of the COVID-19 global pandemic that is of unprecedented proportions and the tremendous need to control the COVID-19 Pneumonia.

Aspire’s decision was supported by our scientific and clinical evaluation of the recent clinical study publication conducted by a research team led by Robert Chunhua Zhao in Beijing YouAn Hospital in China showing that MSCs (Mesenchymal Stem Cells) improves the outcome of patients with COVID-19 pneumonia by possibly controlling the cytokine storm.

About ACT-20

Aspire’s ACT-20 is an allogeneic cryopreserved cell preparation of human Mesenchymal Stem Cells (MSCs) that are ex-vivo culture expanded from human umbilical cord tissue, and the conditioned media (MSC-CM) produced from the culture of the umbilical cord derived MSCs.

MSCs have been previously used in clinical studies for immune modulation of inflammatory diseases such as graft-versus-host disease (GVHD) and systemic lupus erythematosus (SLE). Further, Conditioned Media from MSCs contains metabolites, growth factors, and extracellular matrix proteins secreted by the cultured cells. Published preclinical studies have reported that treatment with MSC conditioned media reduced inflammatory influx, improved alveolar structure, reduced neutrophil influx, and reduced pro-inflammatory cytokines in acute lung injury models.

About Aspire Health Science, LLC

Aspire health Science, LLC is an FDA registered manufacturing facility specialized in development and manufacturing of cell-based therapies.